This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Yuste, L. Articles by Pandiella, A. Search for Related Content PubMed PubMed Citation Articles by Yuste, L. Articles by Pandiella, A.

Activation of ErbB2 by Overexpression or by Transmembrane Neuregulin Results in Differential Signaling and Sensitivity to Herceptin

Instituto de Microbiología Bioquímica and Centro de Investigación del Cáncer, CSIC, Universidad de Salamanca, Salamanca, Spain

Requests for reprints: Atanasio Pandiella, Centro de Investigación del Cáncer, Campus Miguel de Unamuno, 37007 Salamanca, Spain. Phone: 34-923-294815; E-mail: atanasio{at}usal.es.

The ligands of the epidermal growth factor family and their receptors, the ErbB proteins, have been linked to the development of different types of cancer. Particular attention has focused on ErbB2, whose activation may occur by receptor overexpression or by ligand-induced oligomerization with other ErbB receptors. Whether these two modes of ErbB2 activation cause the same biological responses is unknown. Here, we uncovered important differences in the signaling, proliferation rates, and the response to anti-ErbB2 antibodies when comparing MCF7 cells expressing the ligand neuregulin, to MCF7 cells overexpressing ErbB2. Expression of neuregulin caused higher proliferation than ErbB2 overexpression. Transmembrane neuregulin expression was accompanied by constitutive activation of ErbB2, ErbB3, and ErbB4 receptors. ErbB2 overexpression caused tyrosine phosphorylation of ErbB2, whereas ErbB3 and ErbB4 were only slightly tyrosine phosphorylated. Autocrine transmembrane neuregulin also caused constitutive activation of several signaling pathways, such as the Erk1/2, Erk5, and Akt routes, which have been linked to breast cancer cell proliferation. Interestingly, expression of neuregulin increased p21 levels and this was required for the proliferation of MCF7 cells. Treatment with the anti-ErbB2 receptor antibody Herceptin had an inhibitory effect on proliferation only in cells expressing neuregulin but not on cells overexpressing ErbB2, and its inhibitory activity was accompanied by a decrease in p21. These results suggest that Herceptin may also be of help in the treatment of tumors in which neuregulin feeds the tumoral tissue.

This article has been cited by other articles:

				S. W. Warrenfeltz, S. A. Lott, T. M. Palmer, J. C. Gray, and D. Puett Luteinizing Hormone-Induced Up-Regulation of ErbB-2 Is Insufficient Stimulant of Growth and Invasion in Ovarian Cancer Cells Mol. Cancer Res., November 1, 2008; 6(11): 1775 - 1785. [Abstract] [Full Text] [PDF]

				A. Esparis-Ogando, A. Ocana, R. Rodriguez-Barrueco, L. Ferreira, J. Borges, and A. Pandiella Synergic antitumoral effect of an IGF-IR inhibitor and trastuzumab on HER2-overexpressing breast cancer cells Ann. Onc., November 1, 2008; 19(11): 1860 - 1869. [Abstract] [Full Text] [PDF]

				J. C. Montero, R. Rodriguez-Barrueco, A. Ocana, E. Diaz-Rodriguez, A. Esparis-Ogando, and A. Pandiella Neuregulins and Cancer Clin. Cancer Res., June 1, 2008; 14(11): 3237 - 3241. [Abstract] [Full Text] [PDF]

				E. de Alava, A. Ocana, M. Abad, J. C. Montero, A. Esparis-Ogando, C. A. Rodriguez, A. P. Otero, T. Hernandez, J. J. Cruz, and A. Pandiella Neuregulin Expression Modulates Clinical Response to Trastuzumab in Patients With Metastatic Breast Cancer J. Clin. Oncol., July 1, 2007; 25(19): 2656 - 2663. [Abstract] [Full Text] [PDF]

				J. H. Ostrander, A. R. Daniel, K. Lofgren, C. G. Kleer, and C. A. Lange Breast Tumor Kinase (Protein Tyrosine Kinase 6) Regulates Heregulin-Induced Activation of ERK5 and p38 MAP Kinases in Breast Cancer Cells Cancer Res., May 1, 2007; 67(9): 4199 - 4209. [Abstract] [Full Text] [PDF]

				J. C. Montero, R. Rodriguez-Barrueco, L. Yuste, P. P. Juanes, J. Borges, A. Esparis-Ogando, and A. Pandiella The Extracellular Linker of pro-Neuregulin-{alpha}2c Is Required for Efficient Sorting and Juxtacrine Function Mol. Biol. Cell, February 1, 2007; 18(2): 380 - 393. [Abstract] [Full Text] [PDF]

				J. Garaude, S. Cherni, S. Kaminski, E. Delepine, C. Chable-Bessia, M. Benkirane, J. Borges, A. Pandiella, M. A. Iniguez, M. Fresno, et al. ERK5 Activates NF-{kappa}B in Leukemic T Cells and Is Essential for Their Growth In Vivo J. Immunol., December 1, 2006; 177(11): 7607 - 7617. [Abstract] [Full Text] [PDF]

				J. A. Menendez, I. Mehmi, and R. Lupu Trastuzumab in Combination With Heregulin-Activated Her-2 (erbB-2) Triggers a Receptor-Enhanced Chemosensitivity Effect in the Absence of Her-2 Overexpression J. Clin. Oncol., August 10, 2006; 24(23): 3735 - 3746. [Abstract] [Full Text] [PDF]

				C. L. Arteaga Can Trastuzumab Be Effective Against Tumors With Low HER2/Neu (ErbB2) Receptors? J. Clin. Oncol., August 10, 2006; 24(23): 3722 - 3725. [Full Text] [PDF]